DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Conditions: Ductal Carcinoma in Situ Interventions: Drug: Tamoxifen; Drug: Exemestane; Drug: Letrozole; Drug: Anastrazole; Drug: T+Ai; Drug: Elacestrant Sponsors: QuantumLeap Healthcare Collaborative Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Research | Tamoxifen